|
BrachyBytes Editorial Advisory Board
Robert Kuske, M.D. Jay Reiff, Ph.D.
Dan Scanderbeg, Ph.D.
John Sweet, M.S.
Catheryn Yashar, M.D.
Vic Zannis, M.D.
|
|
|
Oncoplastic Surgery: A Radiation Oncologist's Perspective
Robert Kuske, MD
In Part 1 of our Oncoplastic Surgery series, Gail Lebovic, MD, gave a surgeon's perspective on this increasingly popular surgical approach. In Part 2, radiation oncologist and brachytherapy pioneer Robert Kuske, MD, discusses his views on oncoplastic surgery - including why partial breast radiation and oncoplastic surgery are not mutually exclusive treatment options. Read more
Stay tuned for the final installment of our three-part series, in which a surgeon discusses specific techniques for incorporating an APBI device with oncoplastic surgery.
|
|
BC3 Educational Sessions on Oncoplastic Surgery
If you're looking to integrate the principles of oncoplastic surgery into your practice, proper education and training will be essential to your success.
Oncoplastic surgery was a popular topic at the 2011 BC3 Conference, as plastic surgeons, breast surgeons and radiation oncologists presented their perspectives during the "Approaches to Oncoplastic Surgery" series.
Even if you weren't among the more than 900 conference attendees, you can still access the education sessions online for free! Be sure to check out Dr. Robert Kuske's presentation, A Radiation Oncologist's Perspective on Oncoplastic Surgery.
To view the presentations, click here and register by entering your email address.
An email will automatically be sent to you with the direct link to the BC3 education video index page. You can watch the education sessions as many times as you wish. (No CME credits are awarded for viewing the videos.)
Save the Date! 2012 BC3 CME Conference July 19-21, 2012 Washington, D.C. |
|
Drug Can Reduce Risk of Breast Cancer, Study Says
A study presented at the annual meeting of the American Society of Clinical Oncology and published online by the New England Journal of Medicine indicates exemestane (brand name Aromasin), which is now used to prevent recurrences of breast cancer, can also reduce the risk of it occurring in the first place.
The trial involved 4,560 post-menopausal women in the United States, Canada, France and Spain who were considered to be at a higher than normal risk of developing breast cancer. According to the findings, exemestane significantly reduced invasive and pre-invasive breast cancers with no serious toxicities.
Based on the study, researchers recommend exemestane be considered a new option for primary prevention of breast cancer.
Read full article from The New England Journal of Medicine |
|
|
|
|
